The Trump administration has indicated it will make this month's cost-sharing reduction payments to health insurers, according to news reports yesterday. Insurers use the federal payments to reduce out-of-pocket costs for low-income individuals purchasing coverage through the Health Insurance Marketplaces. The Congressional Budget Office this week estimated that premiums for silver-level plans would be 20% higher in 2018 and 25% higher in 2026 if the payments were to end. The U.S. Court of Appeals for the District of Columbia Circuit this month allowed 15 states and the District of Columbia to intervene in the House v. Price lawsuit, which challenges the CSR payments, because they would suffer concrete injury if the payments ended. In a friend-of-the-court brief last year, the AHA and other hospital groups said ending the CSRs would harm patients’ finances and health, trigger a “death spiral” in the marketplaces, and force hospitals to shoulder an even greater financial burden, making it harder for them to serve their communities.

Related News Articles

Headline
Medicaid enrollment decreased 7.6% in fiscal year 2025 and is expected to be mostly flat in FY 2026, according to KFF’s annual Medicaid Budget Survey released…
Blog
Public
The health care field has entered a period of disruption, from sweeping coverage changes to the rise of artificial intelligence (AI)-enabled tools. The…
Headline
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned…
Headline
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed…
Headline
The AHA collaborated with LCMC Health in New Orleans to spotlight innovative efforts that extend care beyond hospital walls. LCMC Health supports families…
Headline
Cigna’s Evernorth division Oct. 27 announced a new, rebate-free pharmacy benefit model, beginning in 2027, that would reduce monthly prescription drug costs by…